Browse Trials
In response to COVID-19, some breast cancer trials have temporarily stopped enrolling new patients. Use the contact information in our trial listings to call or email the research site for information about a trial's status.
Visit COVID-19 & Cancer Clinical Trials on Metastatic Trial Talk for regularly updated information about clinical trials during the coronavirus pandemic.
Currently viewing trials
(Last updated: May 21, 2020)
BRCA1/2
Chemotherapy
Hormone Therapy
Radiation Oncology
Surgery
Surgery: Reconstruction
Targeted Therapy: All
Targeted Therapy: Anti-HER2 Therapy
Targeted Therapy: CDK Inhibitors
Targeted Therapy: PARP Inhibitors
Targeted Therapy: Tumor Mutations
Targeted Therapy: Other Targeted Therapy
Vaccines and Immunotherapy
Other Treatment
Activities
Complementary and Alternative Medicine
Decision Support
Diagnosing Breast Cancer
Genetics/Family History
Having Children
Lymphedema
Managing Side Effects
No Travel Required
Predicting Response to Treatment
Preventing Breast Cancer
Preventing Recurrence
Screening
Support/Education
Surveys/Interviews/Registries
NEAREST SITE: 2 miles
Zuckerberg San Francisco General Hospital
San Francisco,CA
VISITS: 3 or 5 visits over 5 years
PHASE: III
NCT ID: NCT03233191
Digital Tomosynthesis Mammography for Breast Cancer Screening
Tomosynthesis Mammographic Imaging Screening Trial (TMIST) Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard digital (2D) mammogram, once a year for 5 years if pre-menopausal; every other year for 5 years if post-menopausal</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Digital tomosynthesis (3D) mammogram, once a year for 5 years if pre-menopausal; every other year for 5 years if post-menopausal</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Digital tomosynthesis (3D) mammography is approved by the FDA but is not considered the standard of care for breast cancer screening. </li> <li class="seamTextUnorderedListItem">Digital (2D) mammography is the standard of care for breast cancer screening.</li> </ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03233191' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/symptoms/testing/types/dig_tomosynth' target='_blank'>Breastcancer.org: Digital Tomosynthesis</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.hopkinsmedicine.org/breast_center/treatments_services/breast_cancer_screening/digital_mammography/index.html' target='_blank'>Johns Hopkins Medicine: Digital Mammography</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/cancer-currents-blog/2017/tmist-breast-cancer-screening' target='_blank'>NCI: TMIST Trial Aims to Provide Clarity on Breast Cancer Screening Approaches</a> </li></ul>
NEAREST SITE: 3 miles
University of California San Francisco
San Francisco,CA
VISITS: Online surveys
PHASE: NA
NCT ID: NCT02620852
WISDOM Study: Women Informed to Screen Depending on Measures of Risk
Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Risk-Based Screening</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Screening advice based on comprehensive risk assessment </li> <li class="seamTextUnorderedListItem">Saliva sample genetic testing </li> <li class="seamTextUnorderedListItem">Health questionnaires </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard Annual Screening</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Screening advice based on basic risk assessment </li> <li class="seamTextUnorderedListItem">Health questionnaires</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Personalized risk-based screening will take multiple risk factors into consideration, including genetic markers, to determine how often you should have a mammogram.</li> <li class="seamTextUnorderedListItem">This study will help researchers learn if risk-based screening, which helps women learn more about their personal breast cancer risk, is less stressful and as successful at detecting breast cancer through annual screening. </li> <li class="seamTextUnorderedListItem">This study is available in English and Spanish.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02620852' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.athenacarenetwork.org/wisdom-study' target='_blank'>WISDOM Study</a> </li></ul>
NEAREST SITE: 2438 miles
Walter Reed Army Medical Center
Washington,DC
VISITS: 1 visit
PHASE: NA
NCT ID: NCT01322750
A Blood Test for Circulating Tumor Cells for Cancer Screening
Circulating Tumor Cells (CTCs): A Potential Screening Test for Clinically Undetectable Breast Carcinoma Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> All participants will have their blood drawn.</p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Scientists are trying to identify effective new techniques for breast cancer screening. </li> <li class="seamTextUnorderedListItem">Researchers now believe that breast cancer cells can leave the breast and move through the blood stream to other parts of the body before the tumor is even clinically detectable. </li> <li class="seamTextUnorderedListItem">Reliable and accurate detection of these circulating tumor cells (CTCs) is now possible with a simple blood test. </li> <li class="seamTextUnorderedListItem">To be eligible, participants must be military health care beneficiaries.</li> </ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01322750' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/symptoms/testing/types/blood_marker.jsp' target='_blank'>BreastCancer.org: Blood Marker Tests</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancer.gov/cancertopics/screening/breast' target='_blank'>Cancer.gov: Screening and Testing to Detect Cancer</a> </li></ul>
